Publicacións en colaboración con investigadores/as de Hospital Vall d'Hebron (28)

2023

  1. Cardiogenic shock code 2023. Expert document for a multidisciplinary organization that allows quality care

    Revista Espanola de Cardiologia, Vol. 76, Núm. 4, pp. 261-269

  2. Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease

    Nefrologia, Vol. 43, Núm. 4, pp. 386-398

  3. Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis

    Journal of cardiovascular pharmacology, Vol. 81, Núm. 1, pp. 70-75

2022

  1. Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 12

  2. Sex Differences in Low-Density Lipoprotein Cholesterol Reduction with PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry

    Journal of Cardiovascular Pharmacology, Vol. 79, Núm. 4, pp. 523-529

2021

  1. Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI)

    Basic Research in Cardiology, Vol. 116, Núm. 1

2020

  1. Reducing residual thrombotic risk in patients with peripheral artery disease: Impact of the COMPASS trial

    Drugs in Context, Vol. 9

  2. Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition

    Expert Review of Clinical Pharmacology, Vol. 13, Núm. 7, pp. 695-706

2019

  1. Estimated Percentage of Patients With Stable Coronary Heart Disease Candidates for PCSK9 Inhibitors

    Revista Espanola de Cardiologia

2018

  1. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: A multicenter, double-blind, randomized clinical trial

    European Heart Journal, Vol. 39, Núm. 15, pp. 1255-1264

2016

  1. Change of concept about the regulation of angiotensin II-induced monocyte chemoattractant protein-1 production in human endothelial cells

    Vascular Pharmacology, Vol. 80, pp. 20-34

  2. Degree of Lipid Control in Patients With Coronary Heart Disease and Measures Adopted by Physicians. REPAR Study

    Revista Espanola de Cardiologia, Vol. 69, Núm. 10, pp. 931-938

  3. Insuficiente control de parámetros lipídicos en pacientes con enfermedad coronaria: un problema por resolver. Respuesta

    Revista Espanola de Cardiologia

  4. Necesidades no cubiertas con el tratamiento hipolipemiante oral: documento de posición de la Sociedad Española de Cardiología

    Revista Espanola de Cardiologia, Vol. 69, Núm. 11, pp. 1083-1087

  5. Tendencias en factores de riesgo y tratamientos de pacientes con cardiopatía isquémica estable atendidos en consultas de cardiología entre 2006 y 2014

    Revista Espanola de Cardiologia, Vol. 69, Núm. 4, pp. 401-407

2015

  1. Advanced glycation end-products as long-term predictors of death and reinfarction after an acute coronary syndrome

    Biomarkers in Medicine, Vol. 9, Núm. 3, pp. 209-216

  2. Diagnóstico y tratamiento de la hipercolesterolemia familiar en España: Documento de consenso

    Atencion Primaria

  3. Key structural and functional differences between early and advanced glycation products

    Journal of Molecular Endocrinology, Vol. 56, Núm. 1, pp. 23-37

  4. Novedades en cardiología: Riesgo vascular y rehabilitación cardiaca

    Revista Espanola de Cardiologia, Vol. 68, Núm. 2, pp. 136-143

2014

  1. Temas de actualidad en cardiología: riesgo vascular y rehabilitación cardiaca

    Revista Espanola de Cardiologia, Vol. 67, Núm. 3, pp. 203-210